Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (5772)	2/28/2002 2:09:28 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

>> Why one should not try anti-CD2/anti-TNF combination? << Because it makes little sense. If the effector cell is gone, you won't need anti-"effector cell product". >> So far "new biologic" show only 30-35% response rate << If you look at the highest sq and i.v. doses in those small phase II trials, 507 yielded about 40% PASI 75. As you know, it's an extremely potent treatment. Either it will work or it won't. If it does, (1) it should obviate the need for anti-TNF, and (2) I believe that responses would improve with time. If you take anti-TNF and encounter Listeria (or a variety of other bugs), I believe that you stand an increased chance of dying. If you specifically tolerize/remove the population of T cells that is mediating an autoimmune disease, you've done no harm AND you've removed the cells that were producing the TNF, IL-1, etc. The story is still out, and medicines replace good medicines. I have great respect for Enbrel, more all the time. (thanks Sales!) Rick